GlaxoSmithKline is recalling more than 427,000 tubes of mupirocin calcium 2% creams and ointments in various sizes due to penicillin cross contamination and the presence of particulates.
The products were all produced at the company’s Worthing, UK plant, and four separate recalls were launched on Aug. 13.
The nationwide Class II recalls involve a total of 22 lots: six lots of Bactroban nasal ointment, one lot of Bactroban ointment, three lots of Bactroban cream, and 12 lots of mupirocin calcium cream. The antibacterial is used to treat skin infections.
The company is currently assessing the potential for shortages in the U.S., Turkey and Pakistan, spokeswoman Marti Skold Jordan said. The product isn’t being recalled in the two Middle Eastern countries, but shipments may be affected.
To view the FDA Enforcement Reports, go to www.fdanews.com/09-08-15-BactrobanNasal.pdf, http://www.fdanews.com/09-08-15-BactrobanOintment.pdf, www.fdanews.com/09-08-15-BactrobanCream.pdf and www.fdanews.com/09-08-15-MupirocinCalcium.pdf. — Kellen Owings